<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30060358</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>08</Month>            <Day>08</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">0253-3766</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>40</Volume>                    <Issue>7</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                        <Day>23</Day>                    </PubDate>                </JournalIssue>                <Title>Zhonghua zhong liu za zhi [Chinese journal of oncology]</Title>                <ISOAbbreviation>Zhonghua Zhong Liu Za Zhi</ISOAbbreviation>            </Journal>            <ArticleTitle>[Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].</ArticleTitle>            <Pagination>                <MedlinePgn>506-511</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.0253-3766.2018.07.005</ELocationID>            <Abstract>                <AbstractText><b>Objective:</b> To investigate the clinical outcome of expression discordance of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) in primary breast cancer and the corresponding metastatic lesions. <b>Methods:</b> A retrospective analysis was performed on 178 breast cancer patients with metastasis confirmed by the National Cancer Center &amp; Cancer Hospital, Chinese Academy of Medical Sciences in the past 6 years. The data of expressions of ER, PR and HER-2 in primary and metastatic breast cancer, the metastatic sites, disease progression were collected and the relationships of the expression discordance of receptors with prognosis were analyzed. <b>Results:</b> The discordance rates of ER, PR and HER-2 between the primary tumor and the metastatic sites were 27.0%, 39.8% and 18.7%, respectively. The discordance rates of ER, PR and HER-2 of patients with locoregional recurrence were 21.9%, 36.6% and 12.7%, respectively, while those of patients with distant metastases were 31.3%, 42.7% and 23.8%. The median progression free survivals (PFS) of ER+/+、ER+/-、ER-/+、ER-/- of primary tumor and metastatic sites were 17.7 months, 10.3 months, 14.0 months and 9.0months, respectively (<i>P</i>=0.025). The median PFS of PR+/+, PR+/-, PR-/+, PR-/- were 23.0 months, 10.7 months, 14.0 months and 9.2months, respectively (<i>P</i>=0.002). The median PFS of HER-2+/+, HER-2+/-, HER-2-/+, HER-2-/- were 14.9 months, 15.2 months, 12.3 months and 14.0 months, respectively, without significant differences (<i>P</i>=0.588). <b>Conclusions:</b> This study confirms that expression discordances of ER, PR and HER-2 between primary breast cancer and the corresponding metastatic lesions are dramatic, especially in the patients with distant metastasis. The unstable levels of ER and PR seem to be significantly associated with prognosis of breast patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mu</LastName>                    <ForeName>Y X</ForeName>                    <Initials>YX</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>P</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ma</LastName>                    <ForeName>F</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yuan</LastName>                    <ForeName>P</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>J Y</ForeName>                    <Initials>JY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>B H</ForeName>                    <Initials>BH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Q</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>chi</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>China</Country>            <MedlineTA>Zhonghua Zhong Liu Za Zhi</MedlineTA>            <NlmUniqueID>7910681</NlmUniqueID>            <ISSNLinking>0253-3766</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <OtherAbstract Type="Publisher" Language="chi">            <AbstractText><b>目的：</b> 探讨雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)在乳腺癌原发灶和转移灶的异质性及其对患者预后的影响。 <b>方法：</b> 回顾性分析2010年5月至2016年6月间中国医学科学院肿瘤医院收治的178例行乳腺癌转移灶活检患者的临床资料，分析ER、PR和HER-2在乳腺癌原发灶和转移灶的表达情况、转移部位、疾病进展情况和受体表达异质性与患者预后的关系。 <b>结果：</b> 全组患者ER、PR和HER-2在原发灶和转移灶中表达的不一致率分别为27.0%、39.8%和18.7%；在局部复发转移患者中，ER、PR和HER-2表达的不一致率分别为21.9%、36.6%和12.7%；在远处转移患者中，ER、PR和HER-2表达的不一致率分别为31.3%、42.7%和23.8%。ER原发灶阳性转移灶阳性、原发灶阳性转移灶阴性、原发灶阴性转移灶阳性和原发灶阴性转移灶阴性患者的无进展生存时间(PFS)分别为17.7、10.3、14.0和9.0个月，差异有统计学意义(<i>P</i>=0.025)；PR原发灶阳性转移灶阳性、原发灶阳性转移灶阴性、原发灶阴性转移灶阳性和原发灶阴性转移灶阴性患者的中位PFS分别为23.0、10.7、14.0和9.2个月，差异有统计学意义(<i>P</i>=0.002)；HER-2原发灶阳性转移灶阳性、原发灶阳性转移灶阴性、原发灶阴性转移灶阳性和原发灶阴性转移灶阴性患者的中位PFS分别为14.9、15.2、12.3和14.0个月，差异无统计学意义(<i>P</i>=0.588)。 <b>结论：</b> 乳腺癌原发灶和转移灶中ER、PR和HER-2受体表达存在异质性，在远处转移患者中较局部复发转移患者多见，激素受体的改变与患者的预后有关。.</AbstractText>        </OtherAbstract>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">Heterogeneity</Keyword>            <Keyword MajorTopicYN="N">Neoplasm metastasis</Keyword>            <Keyword MajorTopicYN="N">Prognosis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30060358</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>